Qlaris Bio announced the initiation and dosing of two phase 2 trials aimed at assessing QLS-111, a therapy for lowering intraocular pressure by targeting episcleral venous pressure, or EVP, in patients with glaucoma.
The ATP-sensitive potassium channel modulator is designed to reduce IOP by targeting EVP and distal outflow resistance, according to a press release No current medications directly address distal outflow or EVP, according to the release.
“Despite the number of therapies currently available to clinicians, there remains a critical unmet need for new drugs that target unique